Abstract LB-216: Integrated analysis of differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer. Read more about Abstract LB-216: Integrated analysis of differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer.
Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL. Read more about Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL.
Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies. Read more about Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies.
Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro. Read more about Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro.
Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro. Read more about Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro.
Abstract SY06-02: Activation of the UPR by c-Myc promotes transformation and tumorigenesis via cytoprotective autophagy. Read more about Abstract SY06-02: Activation of the UPR by c-Myc promotes transformation and tumorigenesis via cytoprotective autophagy.
